Status:
COMPLETED
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension
Eligibility Criteria
Inclusion
- Age: 20 - 80 years old
- Gender: Male or female
- Status: Outpatients
- severe hypertension
Exclusion
- Patients with a clinically significant allergy
- Patients who have received other investigational drug
- Alcoholic patients
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00299806
Start Date
April 1 2006
End Date
November 1 2006
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Japan, Japan